Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

BACKGROUND: ARCHER 1050, an ongoing, randomized, open-label, phase III trial of dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) and an EGFR-activating mutation, reported significant improvement in overall survival (OS) with dacomitinib. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Mok, Tony S., Cheng, Ying, Zhou, Xiangdong, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Niho, Seiji, Chawla, Alka, Rosell, Rafael, Corral, Jesus, Migliorino, Maria Rita, Pluzanski, Adam, Noonan, Kay, Tang, Yiyun, Pastel, Malaika, Wilner, Keith D., Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932969/
https://www.ncbi.nlm.nih.gov/pubmed/33331989
http://dx.doi.org/10.1007/s40265-020-01441-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932969/
https://www.ncbi.nlm.nih.gov/pubmed/33331989
http://dx.doi.org/10.1007/s40265-020-01441-6

Ejemplares similares